Artificial Intelligence in Cardiovascular Imaging and Risk Stratification: From Algorithmic Discovery to Meaningful Clinical Implication.
Authors
Affiliations (5)
Affiliations (5)
- School of Nursing, Shandong XieHe University, Jinan, Shandong, China.
- School of Information Engineering, Yango University, Fuzhou 350015, China; Institute of Intelligent Algorithms and Complex Systems, Yango University, Fuzhou 350015, China; Institute of Industrial Internet Intelligent Control Technology and System in Universities of Fujian Province, 350015, Fuzhou, Fujian, China; Hong Kong Centre for Cerebro Cardiovascular Health Engineering, Hong Kong. Electronic address: [email protected].
- MBBS, Yangtze University, Jingzhou, Hubei, 434023, China.
- School of Information Engineering, Yango University, Fuzhou 350015, China; Institute of Intelligent Algorithms and Complex Systems, Yango University, Fuzhou 350015, China; Institute of Industrial Internet Intelligent Control Technology and System in Universities of Fujian Province, 350015, Fuzhou, Fujian, China.
- School of Medicine, City University of Hong Kong, Kowloon Tong, Hong Kong.
Abstract
Cardiovascular disease (CVD) remains the leading global cause of mortality, with timely diagnosis and precise risk stratification serving as cornerstones of effective management. Traditional cardiovascular imaging and risk assessment have long been constrained by operator-dependent interpretation, time-intensive manual quantification, and a reliance on static, population-derived diagnostic thresholds. The rapid maturation of artificial intelligence (AI), particularly deep learning (DL), foundation models (FMs), and multimodal integration (MI), has catalyzed a paradigm shift toward automated, quantitative, and patient-specific cardiovascular evaluation. Between 2023 and 2026, AI-driven tools have progressed from retrospective proof-of-concept studies to early prospective clinical validations across echocardiography (EchoCG), cardiac magnetic resonance (CMR), coronary computed tomography angiography (CCTA), and nuclear imaging. Concurrently, AI-enhanced electrocardiography (ECG) and polygenic risk integration have enabled dynamic, longitudinal risk prediction models that outperform conventional scores. Despite these advances, clinical adoption faces substantial hurdles including algorithmic bias, limited generalizability across diverse populations, regulatory fragmentation, workflow integration challenges, and unresolved questions regarding clinical utility and cost-effectiveness. This review critically examines the technological evolution of AI in cardiovascular imaging, evaluates modality-specific applications and emerging digital biomarkers, appraises regulatory and implementation landscapes, and outlines priority research directions. We emphasize that successful integration of AI into cardiovascular care requires rigorous prospective validation, transparent algorithmic governance, equitable data representation, and human-AI collaborative frameworks. As cardiovascular medicine enters the era of precision diagnostics, AI will increasingly serve as a powerful augmentative partner in imaging interpretation, risk stratification, and therapeutic decision-making, provided its meaningful clinical implication is demonstrated through improved patient outcomes.